The FDA has approved carbachol and brimonidine tartrate (Yuvezzi; Tenpoint Therapeutics, Ltd), a fixed-dose ophthalmic combination for the treatment of presbyopia—an age-related, near vision loss condition. Yuvezzi combines carbachol and brimonidine tartrate, 2 FDA-approved glaucoma therapies, to treat presbyopia. “I’m excited that I will be able to offer my patients [brimonidine tartrate and carbachol], the first-of-its-kind eye drop well-suited for long-term use. Tenpoint Therapeutics Ltd. announces FDA approval of Yuvezzi, the first and only combination eye drop approved to treat presbyopia. Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia.